Experts across a wide range of disciplines at Imperial College London have been – and are continuing – to keep government and society informed about COVID-19, save lives through vaccines and testing – and providing solutions to protect the NHS.
COVID-19 vaccine candidate
As the first trials of Imperial’s COVID-19 vaccine candidate got underway in June, the team leading this pioneering work talk though the science of the vaccine and how they will find out whether it protects people from the disease.
In the video below, Professor Robin Shattock, Dr Katrina Pollock and Dr David Owen explain how the vaccine works, how it’s being trialled, and plans to help it reach populations around the world, if it proves to be effective in protecting people against COVID-19.
Coronavirus testing kits: DnaNudge
DnaNudge is a lab-free, rapid and reliable PCR test which delivers results in under 90 minutes developed by an Imperial startup, headquartered in White City. Originally designed to encourage healthier dietary choices for customers, the product has been adapted to test for COVID19 with the government placing a £161 million order for 5.8 million DnaNudge COVID-19 test kits to be used in NHS hospitals from September in urgent patient care and elective surgery settings, with further deployments in out-of-hospital settings later on.
The 90-minute COVID-19 test has been shown to have over 94 per cent sensitivity, and 100 per cent specificity in a new study, published in the journal The Lancet Microbe,
“You take a swab and put it in the cartridge and it doesn’t need any more handling, so you can do this in an A&E, on a ward, and you get much faster turnaround on that result…We have it now in eight hospitals in West London and we’re starting to use it to make clinical decisions…it has a very high certainty of detecting virus and also not giving a false positive result, so we can use that in real time to make decisions.” – Professor Graham Cooke, from the Department of Infectious Disease, advised Today Programme, BBC Radio 4 (From 0h 47m 35s)
“I am hugely grateful to DnaNudge and their incredible work to innovate coronavirus testing, which will mean we can test millions more people in the coming months”. Matt Hancock MP, Health Secretary
JAMVENT – Ventilator
In response to the COVID crisis, Imperial’s experts in medical device design – and a clinician treating infected patients – designed a ventilator that can be built to meet MHRA and FDA requirements using generic parts.
JAMVENT provides a simple, low-cost solution to ventilator shortages worldwide, particularly for health services in developing countries. Plus the robust design also makes it suitable for long term use beyond current COVID-19 needs.
The design document for JAMVENT can be downloaded by those wishing to develop ventilators for their local healthcare providers. It includes a list of parts and a software spec – plus any further updates will also be made available. Enquiries from health organisations, manufacturers and donors interested in taking JAMVENT from design to manufacture are also welcome.
Dr Joseph Sherwood and Dr Jakob Mathiszig-Lee demonstrate JAMVENT.
PPE for healthcare workers
The Imperial College Advanced Hackspace and the NIHR Health Protection Research Unit developed, optimised and evaluated visors to ensure they were appropriate for use – and Imperial volunteers set about making more than 50,000 disposable visors for Imperial College Healthcare NHS Trust hospitals. Rolls Royce Motor Cars also provided the first 7,000 visors kits for the team to assemble .
Imperial College COVID-19 Response Fund
This donor backed fund continues to help researchers, from a wide range of disciplines, win the battle against COVID-19. The latest projects to receive funding aim to…
- Speed up and enhance testing using nanotechnology and existing diagnostic instruments
- Support the NHS by addressing the discomfort of long term PPE use, adapting AI clinical decision support systems and investigating transmission risks to see when staff can return to work
- Analyse patient data and tissue to better understand the disease and explore already-licensed drugs to devise new treatments and therapies
In addition, Dr Georgiou and his team have developed a cutting-edge ‘lab on a chip’ diagnostic platform using microchip technology that can be paired with a smartphone app to rapidly identify whether a person is positive for SARS-CoV-2 RNA from a nasal or throat swab. The low-cost test could offer a portable alternative to lab-based testing, allowing patients to be diagnosed at the bedside, or in the community, in real time.
Tracking trends and learning about disease
- More than 66,000 patients with COVID-19 have so far been enrolled in a UK-wide study to learn more about the disease. Hear more From Professor Openshaw.
- Home testing for coronavirus to track levels of infection in the community
- The REACT programme, commissioned by the Department of Health and Social Care, is monitoring how the virus is spreading across the country.
- A separate study by the Department of Mathematics is tracking COVID-19 ‘hotspots’ as they emerge, to help inform local lockdown policies or introduce mitigation measures to stop the spread of infection
COVID-19 response Fund
The Imperial College COVID-19 Response Fund allows donors to fund high-impact projects in the university’s efforts to tackle COVID-19 and more than 860 people have donated so far.
Study of Italy’s Vo
“Our research shows that testing of all citizens, whether or not they have symptoms, provides a way to manage the spread of disease and prevent outbreaks getting out of hand.” Professor Andrea Crisanti
Jamil Research fund
The Community Jameel Imperial College COVID-19 Excellence Fund was launched in June 2020 to provide support for research projects into the impact, understanding, prevention, diagnosis, and treatment of COVID-19..
The rate of COVID-19 infection in England dropped in June, despite some lockdown restrictions being eased, reveals second report from a major programme of community testing.
AI treatment for COVID-19 patients
Dr Brijesh Patel is leading a trial to test a new AI device to help monitor the lung physiology of patients with severe COVID-19 pneumonia.
Taking part in the COVID-19 vaccine trial
Video ‘catch up’ with a participant in Imperial’s COVID-19 vaccine trial after she receives her first dose, to see how she feels and why she decided to take part.
Who to contact:
For Healthcare, Pharmaceuticals, Public & Global Health, Environment & Climate Change, Business, Maths, Finance
Tel: +44 (0)20 7594 6559